[{"address1": "Wallstrasse 16", "city": "Berlin", "zip": "10179", "country": "Germany", "phone": "49 89 2153 9035", "fax": "49 89 2153 9035 1", "website": "https://www.atai.life", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.", "fullTimeEmployees": 133, "companyOfficers": [{"maxAge": 1, "name": "Mr. Christian  Angermayer", "age": 45, "title": "Founder & Chairman of the Supervisory Board", "yearBorn": 1978, "fiscalYear": 2022, "totalPay": 70000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Florian  Brand", "age": 36, "title": "Co-founder & CEO", "yearBorn": 1987, "fiscalYear": 2022, "totalPay": 835442, "exercisedValue": 0, "unexercisedValue": 9709600}, {"maxAge": 1, "name": "Dr. Srinivas G. Rao M.D., Ph.D.", "age": 54, "title": "Co-Founder & Chief Scientific Officer", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": 834150, "exercisedValue": 0, "unexercisedValue": 457481}, {"maxAge": 1, "name": "Mr. Stephen B. Bardin", "age": 32, "title": "Advisor", "yearBorn": 1991, "fiscalYear": 2022, "totalPay": 651322, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Anne  Johnson", "title": "Chief Financial Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Raven Ph.D.", "title": "Senior Vice President of Operations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frank  Stegert", "age": 42, "title": "Vice President of Investment & Venture Management", "yearBorn": 1981, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Barrett", "age": 42, "title": "Senior VP, General Counsel & Corporate Secretary", "yearBorn": 1981, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Glenn  Short Ph.D.", "title": "Senior Vice President of Early Development", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sahil V. Kirpekar M.D.", "age": 37, "title": "Chief Business Officer", "yearBorn": 1986, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.51, "open": 2.48, "dayLow": 2.32, "dayHigh": 2.5492, "regularMarketPreviousClose": 2.51, "regularMarketOpen": 2.48, "regularMarketDayLow": 2.32, "regularMarketDayHigh": 2.5492, "beta": 0.965, "forwardPE": -3.5000002, "volume": 2488891, "regularMarketVolume": 2488891, "averageVolume": 1734124, "averageVolume10days": 3086240, "averageDailyVolume10Day": 3086240, "bid": 2.42, "ask": 2.47, "bidSize": 200, "askSize": 500, "marketCap": 406724512, "fiftyTwoWeekLow": 1.025, "fiftyTwoWeekHigh": 2.85, "priceToSalesTrailing12Months": 1217.738, "fiftyDayAverage": 1.8804, "twoHundredDayAverage": 1.61125, "currency": "USD", "enterpriseValue": 109369752, "floatShares": 126543145, "sharesOutstanding": 166010000, "sharesShort": 5205386, "sharesShortPriorMonth": 4865063, "sharesShortPreviousMonthDate": 1707955200, "dateShortInterest": 1710460800, "sharesPercentSharesOut": 0.031400003, "heldPercentInsiders": 0.10045, "heldPercentInstitutions": 0.2802, "shortRatio": 3.34, "shortPercentOfFloat": 0.040999997, "impliedSharesOutstanding": 166010000, "bookValue": 1.604, "priceToBook": 1.5274315, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -66943000, "trailingEps": -0.43, "forwardEps": -0.7, "enterpriseToRevenue": 327.454, "enterpriseToEbitda": -0.868, "52WeekChange": 0.44970417, "SandP52WeekChange": 0.26653707, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ATAI", "underlyingSymbol": "ATAI", "shortName": "ATAI Life Sciences N.V.", "longName": "Atai Life Sciences N.V.", "firstTradeDateEpochUtc": 1624023000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "8699f3bf-7398-34d0-b0ba-129948e2583d", "messageBoardId": "finmb_710359021", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.45, "targetHighPrice": 21.0, "targetLowPrice": 5.1, "targetMeanPrice": 10.68, "targetMedianPrice": 8.5, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 208994000, "totalCashPerShare": 1.259, "ebitda": -125998000, "totalDebt": 18969000, "quickRatio": 10.688, "currentRatio": 10.958, "totalRevenue": 334000, "debtToEquity": 7.064, "revenuePerShare": 0.002, "returnOnAssets": -0.24252, "returnOnEquity": -0.25293, "freeCashflow": -42366248, "operatingCashflow": -92661000, "revenueGrowth": 2.625, "grossMargins": 1.0, "operatingMargins": -308.43677, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-07"}]